VEINAMINE 8%
LOE Approachingamino acids; magnesium chloride; potassium acetate; potassium chloride; sodium acetate
NDAINJECTIONINJECTABLE
Approved
Jan 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VEINAMINE 8% is an intravenous amino acid formulation supplemented with electrolytes (magnesium chloride, potassium acetate, potassium chloride, sodium acetate) designed for parenteral nutrition support. It provides essential amino acids and electrolyte balance to patients unable to meet nutritional needs orally. The product supports protein synthesis and metabolic homeostasis in critically ill, post-operative, or nutritionally compromised patients.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%) signals a defensive commercial posture focused on retention and hospital formulary management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VEINAMINE 8% offers stable, defensive commercial experience in hospital nutrition markets with focus on formulary management and clinical relationships rather than innovation. Career growth is limited by product maturity and approaching LOE, making this role suitable for professionals seeking operational expertise or healthcare system relationships in established categories.
Hospital Account Manager
Worked on VEINAMINE 8% at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.